The triglyceride-glucose (TyG) index has been identified as a reliable alternative biomarker
of insulin resistance (IR). Recently, a considerable number of studies have provided robust …

The introduction and subsequent iterations of drug-eluting stent technologies have
substantially improved the efficacy and safety of percutaneous coronary interventions …

Aim The guideline for coronary artery revascularization replaces the 2011 coronary artery
bypass graft surgery and the 2011 and 2015 percutaneous coronary intervention guidelines …

Cardiovascular diseases have become the leading cause of death worldwide. The
increasing burden of cardiovascular diseases has become a major public health problem …

Although drug-eluting stents are still the default interventional treatment of coronary artery
disease, drug-coated balloons (DCBs) represent a novel alternative therapeutic strategy in …

Drug-eluting stents implanted after ischaemic injury reduce the proliferation of endothelial
cells and vascular smooth muscle cells and thus neointimal hyperplasia. However, the …

In-stent restenosis (ISR) remains the most common cause of stent failure after percutaneous
coronary intervention (PCI). Recent data suggest that ISR-PCI accounts for 5-10% of all PCI …

Background There is a paucity of data on the burden of in-stent restenosis (ISR) in the
United States as well as on its presentation and appropriate treatment strategies. Objectives …

Despite on-going evolution and iteration of drug-eluting stent (DES) technology, the
prevalence of in-stent restenosis (ISR) remains relatively unchanged, encompassing≈ 10 …

Modern-day stenting procedures leverage advances in pharmacotherapy and device
innovation. Patients treated with contemporary antiplatelet agents, peri-procedural …